<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:department>Community-Based Medicine</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/00FD6AA2-05F7-496D-B825-61F2CD8CDD16"><gtr:id>00FD6AA2-05F7-496D-B825-61F2CD8CDD16</gtr:id><gtr:firstName>A E</gtr:firstName><gtr:surname>Ades</gtr:surname><gtr:orcidId>0000-0001-7822-3552</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/5033A559-126A-4C8C-9798-8FDCC4C74ACD"><gtr:id>5033A559-126A-4C8C-9798-8FDCC4C74ACD</gtr:id><gtr:firstName>Nicky</gtr:firstName><gtr:otherNames>J</gtr:otherNames><gtr:surname>Welton</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G1001338"><gtr:id>F6C7FDF7-2641-42C7-909B-5803806DB3BC</gtr:id><gtr:title>Analysis and synthesis of time-to-event data from cancer trials in the assessment of cost-effectiveness</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1001338</gtr:grantReference><gtr:abstractText>All new treatments are subjected to an analysis of both their effectiveness and cost-effectiveness before they can be recommended for use in the NHS, and data from randomised clinical trials forms the critical element in these assessments. In the case of cancer treatments these trials generate time-to-event data, which require special methods of analysis because many patients have not reached the trial ?end-point? (tumour progression, or death) at the time when the study data is analysed. It is extraordinary, but true, that the data analysis used to assess effectiveness is almost invariably different from the one used to assess cost-effectiveness, and that the two analyses cannot both be correct. This has lead to an element of arbitrariness in the cost-effectiveness calculations, which depend enormously in what assumptions are made. At NICE, Appraisals Committees are, as a result, frequently confronted with alternative sets of assumptions that lead to completely different conclusions, and this has in the past lead to an Appeal. But even if this were not the case, it is clear that methods for analysing time-to-event data for cost-effectiveness calculations need to be completely overhauled. Current methods for deriving estimates from data, and for extrapolating treatment effects over a lifetime, can be shown in many respects ? perhaps surprisingly ? to be incoherent and non-sensical. This research sets out to establish new analytic procedures and methods, which use the available data fairly and give the best predictions possible about the gain in life-expectancy and quality of life due to the new cancer treatments. The aim is to make the task of assessing these treatments more transparent and less open to arbitrary, and incorrect, assumptions.</gtr:abstractText><gtr:technicalSummary>The efficacy of new cancer treatments is assessed in randomised trials with time-to-event outcomes, and methods for survival data analysis based on Cox regression and proportional hazards are pre-specified in trial protocols, and widely accepted. However, cost-effectiveness analysis (CEA) is an increasingly important, and in some jurisdictions the decisive element in decisions about whether new treatments will be recommended for routine use. Cox regression and hazard ratios, designed for statistical inference, are wholly inadequate as a basis for CEA, which relies on estimated of expected time-to-event. Currently, investigators produce separate analyses of the trial data for the purposes of CEA. Because estimates of expected to-to-event require extrapolation beyond the data, they can be highly sensitive to model choice. In the absence of pre-specified protocols for cost-effectiveness analysis, this leaves conclusions on cost-effectiveness vulnerable to more or les arbitrary model selection. The standard modelling technique used in CEA, the Markov model, cannot correctly capture uncertainty in extrapolation, and is more often than not based on incoherent parameter estimates. The purposes of the research proposed here is to provide a new approach to time-to-event data analysis, fit for the purpose of CEA, that correctly reflects extrapolation uncertainty. We will carry out an exploratory analysis of a representative set of cancer trials, to determine how ?complex? cancer survival curves are in practice, looking at a wide range of models. These will include generalised families of parametric distributions and highly flexible spline functions. We will then conduct simulation studies based on realistically complex models, as dictated by the exploratory analysis, to identify analytic methods and procedures that best recover the expected time-to-event statistics of the generating models. We will also develop new methods for synthesis of evidence from multiple trials, comparing methods based on expected time-to-event estimates, with joint modelling of multiple trials with flexible survival techniques. The research has very wide implications for CEAs in all areas of medicine where time-to-event outcomes are used in trials designed for regulatory approval or re-imbursement decisions, particularly for the design of trial data analysis protocols, and synthesis methods for time-to-event outcomes.</gtr:technicalSummary><gtr:fund><gtr:end>2013-06-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>150497</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Liverpool</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Ashma Krishan PhD</gtr:description><gtr:id>C2F3590E-CE9A-426A-96F9-46785D193D4E</gtr:id><gtr:impact>Non yet</gtr:impact><gtr:partnerContribution>Supervision</gtr:partnerContribution><gtr:piContribution>Supervision</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>InterTASC workshop Survival Analysis. Extrapolation of trial-based survival curves: constraints based on external information</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>48AF0384-1F2C-4F8F-8B64-59AC49A7E5E3</gtr:id><gtr:impact>Presented research to InterTASC group of statisticians, health economists, and systematic reviewers who critique industry submissions made to NICE.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ISPOR Workshop Guidance for evidence synthesis of survival outcomes for cost-effectiveness modelling.</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3C6B3A51-B38A-4675-B38C-E4D0F8CE8945</gtr:id><gtr:impact>workshop on survival analysis presented at ISPOR conference attended by industry, policymakers, and academics. The workshop included discussion and requests for more details.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation at NICE Away Day 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F044350E-3A58-4C18-9E07-47F352B7874B</gtr:id><gtr:impact>Made NICE Committee members and Evidence Review Groups aware of the potential for the use of external information to better inform the shape of survival curves, to help make better reimbursement decisions.

The survival curve reconstruction methods have been used in submissions to NICE technology appraisals. The committee members have an improved understanding of the key issues in extrapolating beyond trial follow-up periods.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited talk Bangor Centre for Health Economics and Medicines Evaluation. Extrapolation of survival curves from cancer trials using external information.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>FEAFF007-3550-40DD-82B0-497608B85A8C</gtr:id><gtr:impact>Presented research to group of health economists at Bangor University, which sparked discussion.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>This software, written in R, takes as input a scanned in image of Kaplan Meier (survival curves), and data on the numbers at risk at different time points (if available). It delivers what is effectively the sufficient statistics for teh K-M curves - ie the &amp;quot;life-table&amp;quot; data from which the KM curves are constructed.

The underlying algorithm is superior to other approaches that have been published in that it guarantees that the results are consistent with the available data. 

The algorithm is published, along with an evaluation, in Guyot P, etal. BMC Med Res Methodol. 2012 Feb 1;12:9.
PMID: 22297116</gtr:description><gtr:id>F0BE1D56-D796-407F-8EE4-493EB0F3F19C</gtr:id><gtr:impact>We expect to see this algorithm widely used, as it permits researchers to access what is effectively the &amp;quot;individual patient data&amp;quot; (but without covariates) from published KM curves, rather than just make use of the reported Hazard Ratios.
It is too early to assess whether this expectation will be borne out</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Reconstruction of Survival-time data from Kaplan Meier curves</gtr:title><gtr:type>Data analysis technique</gtr:type><gtr:url>http://europepmc.org/abstract/MED/22297116</gtr:url><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/166D8B86-8016-4FA4-8EE8-CC490B6F0965"><gtr:id>166D8B86-8016-4FA4-8EE8-CC490B6F0965</gtr:id><gtr:title>Extrapolation of Survival Curves from Cancer Trials Using External Information.</gtr:title><gtr:parentPublicationTitle>Medical decision making : an international journal of the Society for Medical Decision Making</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3e1966ce9dde19752aa6dfac19d28cbc"><gtr:id>3e1966ce9dde19752aa6dfac19d28cbc</gtr:id><gtr:otherNames>Guyot P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0272-989X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EA475745-8A6D-4C70-9E2C-12ACC1DD2086"><gtr:id>EA475745-8A6D-4C70-9E2C-12ACC1DD2086</gtr:id><gtr:title>Survival time outcomes in randomized, controlled trials and meta-analyses: the parallel universes of efficacy and cost-effectiveness.</gtr:title><gtr:parentPublicationTitle>Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3e1966ce9dde19752aa6dfac19d28cbc"><gtr:id>3e1966ce9dde19752aa6dfac19d28cbc</gtr:id><gtr:otherNames>Guyot P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1098-3015</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/40EE04B1-185C-469D-BA90-E7A471449D86"><gtr:id>40EE04B1-185C-469D-BA90-E7A471449D86</gtr:id><gtr:title>Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.</gtr:title><gtr:parentPublicationTitle>BMC medical research methodology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3e1966ce9dde19752aa6dfac19d28cbc"><gtr:id>3e1966ce9dde19752aa6dfac19d28cbc</gtr:id><gtr:otherNames>Guyot P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1471-2288</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1001338</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>237CBF0D-6B87-46FD-A97B-E432D87D3FE6</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>8.2  Health and welfare economics</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>